A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a precision genetic medicines company committed to developing curative therapeutics for patients using our proprietary, genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. Genetic mutations are seen in a variety of forms, including deletions, insertions, single-base-pair changes and sequence repeats, and are found throughout the genome and across a variety of different cell types, tissues, and organ systems. Additionally, many diseases lack a genetic origin but have the potential to be effectively and permanently addressed through genome editing. We are harnessing the power of metagenomics, the study of genetic material recovered from the natural environment, to unlock four billion years of microbial evolution to discover and develop a suite of novel editing tools capable of correcting any type of genetic mutation found anywhere in the genome.
| Metric | TTM | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 31M | 52M | 45M |
| Net Income | -89M | -78M | -68M |
| EPS | $-2.39 | $-2.36 | $-20.05 |
| Free Cash Flow | -92M | -112M | -101M |
| ROIC | -50.0% | -33.2% | -17.0% |
| Gross Margin | - | - | - |
| Debt/Equity | 0.00 | 0.38 | -1.10 |
| Dividends/Share | $0.00 | - | - |
| Operating Income | -92M | -89M | -78M |
| Operating Margin | -298.5% | -170.0% | -175.4% |
| ROE | -49.7% | -157.3% | - |
| Shares Outstanding | 38M | 33M | 37M |
| Metric | 2023 | ||
|---|---|---|---|
| Income Statement | |||
| Revenue | 45M | 52M | 31M |
| Gross Margin | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A |
| EBIT | -78M | -89M | -92M |
| Op. Margin | -175.4% | -170.0% | -298.5% |
| Net Income | -68M | -78M | -89M |
| Net Margin | -152.5% | -149.3% | -287.1% |
| Non-Recurring | 0 | 0 | 0 |
| Returns on Capital | |||
| ROIC | -17.0% | -33.2% | -50.0% |
| ROE | N/A | -157.3% | -49.7% |
| ROA | -18.7% | -22.6% | -35.8% |
| Cash Flow | |||
| Op. Cash Flow | -91M | -109M | -92M |
| Free Cash Flow | -101M | -112M | -92M |
| Owner Earnings | -103M | -131M | -113M |
| CapEx | 9.8M | 3.1M | 823K |
| Maint. CapEx | 4.2M | 5.4M | 5.4M |
| Growth CapEx | 5.6M | 0 | 0 |
| D&A | 4.2M | 5.4M | 5.4M |
| CapEx/OCF | N/A | N/A | 0.0% |
| Capital Allocation | |||
| Dividends Paid | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% |
| Stock-Based Comp | 6.9M | 16M | 16M |
| Debt Repayment | 0 | 0 | 0 |
| Balance Sheet | |||
| Net Debt | N/A | N/A | -33M |
| Cash & Equiv. | N/A | N/A | 33M |
| Long-Term Debt | N/A | N/A | N/A |
| Debt/Equity | -1.10 | 0.38 | 0.00 |
| Interest Coverage | N/A | N/A | N/A |
| Equity | -136M | 235M | 178M |
| Total Assets | 365M | 325M | 248M |
| Total Liabilities | 150M | 90M | 9.9M |
| Intangibles | N/A | N/A | N/A |
| Retained Earnings | -145M | -223M | -223M |
| Working Capital | 209M | 221M | 221M |
| Current Assets | 278M | 258M | 258M |
| Current Liabilities | 69M | 37M | 37M |
| Per Share Data | |||
| EPS | -20.05 | -2.36 | -2.39 |
| Owner EPS | -2.74 | -3.95 | -3.02 |
| Book Value | -3.63 | 7.10 | 4.75 |
| Cash Flow/Share | -2.45 | -3.30 | -2.22 |
| Dividends/Share | N/A | N/A | 0.00 |
| Shares Out. | 37.4M | 33.1M | 37.5M |
| Valuation | |||
| P/E Ratio | N/A | N/A | -0.6 |
| P/FCF | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A |
| Price/Book | N/A | 0.5 | 0.3 |
| Price/Sales | N/A | 3.4 | 1.7 |
| FCF Yield | N/A | -90.7% | -172.2% |
| Market Cap | N/A | 124M | 54M |
| Avg. Price | N/A | 5.35 | 1.43 |
| Year-End Price | N/A | 3.74 | 1.43 |
Metagenomi, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Metagenomi, Inc. (MGX) has a 5-year average return on invested capital (ROIC) of -25.1%. This is below average and may indicate limited pricing power.
Metagenomi, Inc. (MGX) has a market capitalization of $54M. It is classified as a small-cap stock.
Metagenomi, Inc. (MGX) does not currently pay a regular dividend.
Metagenomi, Inc. (MGX) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Metagenomi, Inc. (MGX) reported annual revenue of $52 million in its most recent fiscal year, based on SEC EDGAR filings.
Metagenomi, Inc. (MGX) has a net profit margin of -149.3%. The company is currently unprofitable.
Metagenomi, Inc. (MGX) generated $-112 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Metagenomi, Inc. (MGX) has a debt-to-equity ratio of 0.38. This indicates a conservatively financed balance sheet.
Metagenomi, Inc. (MGX) reported earnings per share (EPS) of $-2.36 in its most recent fiscal year.
Metagenomi, Inc. (MGX) has a return on equity (ROE) of -157.3%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 2 years of financial data for Metagenomi, Inc. (MGX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Metagenomi, Inc. (MGX) has a book value per share of $7.10, based on its most recent annual SEC filing.